CRISPR Therapeutics (CRSP)

The company’s most important commercial milestone is Casgevy, developed with Vertex Pharmaceuticals. Casgevy is an approved CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia, two inherited blood disorders caused by defects in haemoglobin production. The therapy uses ex vivo editing, meaning a patient’s own blood stem cells are collected, modified outside the body, and reinfused after conditioning treatment.

Beyond haemoglobinopathies, CRISPR Therapeutics is building a pipeline across several areas. Its immuno-oncology programmes aim to create engineered cell therapies that can recognise and attack cancer. The company also works on regenerative and stem-cell-derived approaches, including potential treatments for Type 1 diabetes, and explores gene-editing applications in cardiovascular disease and other serious conditions.

As a listed biotech company, CRISPR Therapeutics is shaped by clinical trial progress, regulatory decisions, manufacturing complexity, partnership economics, and the pace of adoption for advanced therapies. Its collaboration with Vertex provides commercial and development support for Casgevy, while its broader pipeline offers longer-term optionality. The company stands out because it is one of the first firms to bring CRISPR medicine from a research breakthrough into approved therapeutic use.